Cargando…
Profiling of patients with type 2 diabetes based on medication adherence data
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a complex, chronic disease affecting multiple organs with varying symptoms and comorbidities. Profiling patients helps identify those with unfavorable disease progression, allowing for tailored therapy and addressing special needs. This study aims to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358769/ https://www.ncbi.nlm.nih.gov/pubmed/37483941 http://dx.doi.org/10.3389/fpubh.2023.1209809 |
_version_ | 1785075736502075392 |
---|---|
author | Markovič, Rene Grubelnik, Vladimir Završnik, Tadej Blažun Vošner, Helena Kokol, Peter Perc, Matjaž Marhl, Marko Završnik, Matej Završnik, Jernej |
author_facet | Markovič, Rene Grubelnik, Vladimir Završnik, Tadej Blažun Vošner, Helena Kokol, Peter Perc, Matjaž Marhl, Marko Završnik, Matej Završnik, Jernej |
author_sort | Markovič, Rene |
collection | PubMed |
description | INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a complex, chronic disease affecting multiple organs with varying symptoms and comorbidities. Profiling patients helps identify those with unfavorable disease progression, allowing for tailored therapy and addressing special needs. This study aims to uncover different T2DM profiles based on medication intake records and laboratory measurements, with a focus on how individuals with diabetes move through disease phases. METHODS: We use medical records from databases of the last 20 years from the Department of Endocrinology and Diabetology of the University Medical Center in Maribor. Using the standard ATC medication classification system, we created a patient-specific drug profile, created using advanced natural language processing methods combined with data mining and hierarchical clustering. RESULTS: Our results show a well-structured profile distribution characterizing different age groups of individuals with diabetes. Interestingly, only two main profiles characterize the early 40–50 age group, and the same is true for the last 80+ age group. One of these profiles includes individuals with diabetes with very low use of various medications, while the other profile includes individuals with diabetes with much higher use. The number in both groups is reciprocal. Conversely, the middle-aged groups are characterized by several distinct profiles with a wide range of medications that are associated with the distinct concomitant complications of T2DM. It is intuitive that the number of profiles increases in the later age groups, but it is not obvious why it is reduced later in the 80+ age group. In this context, further studies are needed to evaluate the contributions of a range of factors, such as drug development, drug adoption, and the impact of mortality associated with all T2DM-related diseases, which characterize these middle-aged groups, particularly those aged 55–75. CONCLUSION: Our approach aligns with existing studies and can be widely implemented without complex or expensive analyses. Treatment and drug use data are readily available in healthcare facilities worldwide, allowing for profiling insights into individuals with diabetes. Integrating data from other departments, such as cardiology and renal disease, may provide a more sophisticated understanding of T2DM patient profiles. |
format | Online Article Text |
id | pubmed-10358769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103587692023-07-21 Profiling of patients with type 2 diabetes based on medication adherence data Markovič, Rene Grubelnik, Vladimir Završnik, Tadej Blažun Vošner, Helena Kokol, Peter Perc, Matjaž Marhl, Marko Završnik, Matej Završnik, Jernej Front Public Health Public Health INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a complex, chronic disease affecting multiple organs with varying symptoms and comorbidities. Profiling patients helps identify those with unfavorable disease progression, allowing for tailored therapy and addressing special needs. This study aims to uncover different T2DM profiles based on medication intake records and laboratory measurements, with a focus on how individuals with diabetes move through disease phases. METHODS: We use medical records from databases of the last 20 years from the Department of Endocrinology and Diabetology of the University Medical Center in Maribor. Using the standard ATC medication classification system, we created a patient-specific drug profile, created using advanced natural language processing methods combined with data mining and hierarchical clustering. RESULTS: Our results show a well-structured profile distribution characterizing different age groups of individuals with diabetes. Interestingly, only two main profiles characterize the early 40–50 age group, and the same is true for the last 80+ age group. One of these profiles includes individuals with diabetes with very low use of various medications, while the other profile includes individuals with diabetes with much higher use. The number in both groups is reciprocal. Conversely, the middle-aged groups are characterized by several distinct profiles with a wide range of medications that are associated with the distinct concomitant complications of T2DM. It is intuitive that the number of profiles increases in the later age groups, but it is not obvious why it is reduced later in the 80+ age group. In this context, further studies are needed to evaluate the contributions of a range of factors, such as drug development, drug adoption, and the impact of mortality associated with all T2DM-related diseases, which characterize these middle-aged groups, particularly those aged 55–75. CONCLUSION: Our approach aligns with existing studies and can be widely implemented without complex or expensive analyses. Treatment and drug use data are readily available in healthcare facilities worldwide, allowing for profiling insights into individuals with diabetes. Integrating data from other departments, such as cardiology and renal disease, may provide a more sophisticated understanding of T2DM patient profiles. Frontiers Media S.A. 2023-07-06 /pmc/articles/PMC10358769/ /pubmed/37483941 http://dx.doi.org/10.3389/fpubh.2023.1209809 Text en Copyright © 2023 Markovič, Grubelnik, Završnik, Blažun Vošner, Kokol, Perc, Marhl, Završnik and Završnik. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Markovič, Rene Grubelnik, Vladimir Završnik, Tadej Blažun Vošner, Helena Kokol, Peter Perc, Matjaž Marhl, Marko Završnik, Matej Završnik, Jernej Profiling of patients with type 2 diabetes based on medication adherence data |
title | Profiling of patients with type 2 diabetes based on medication adherence data |
title_full | Profiling of patients with type 2 diabetes based on medication adherence data |
title_fullStr | Profiling of patients with type 2 diabetes based on medication adherence data |
title_full_unstemmed | Profiling of patients with type 2 diabetes based on medication adherence data |
title_short | Profiling of patients with type 2 diabetes based on medication adherence data |
title_sort | profiling of patients with type 2 diabetes based on medication adherence data |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358769/ https://www.ncbi.nlm.nih.gov/pubmed/37483941 http://dx.doi.org/10.3389/fpubh.2023.1209809 |
work_keys_str_mv | AT markovicrene profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT grubelnikvladimir profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT zavrsniktadej profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT blazunvosnerhelena profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT kokolpeter profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT percmatjaz profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT marhlmarko profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT zavrsnikmatej profilingofpatientswithtype2diabetesbasedonmedicationadherencedata AT zavrsnikjernej profilingofpatientswithtype2diabetesbasedonmedicationadherencedata |